Tretinoin 0.045% | Hydroquinone 6% | Desonide 0.05% | Kojic Acid 4%

Applied topically once nightly to the hyperpigmented skin areas only, on clean, dry skin. Apply a thin layer with a fingertip to affected areas; avoid eyes, nostrils, and lips. Apply broad-spectrum SPF 30+ sunscreen every morning without exception. Do not use occlusive dressings unless directed by the prescriber (increases corticosteroid and hydroquinone absorption).

Apply a thin layer once nightly to hyperpigmented areas. Duration of continuous use should be prescribed by the clinician, typically limited to 3–6 months for the corticosteroid and hydroquinone components. Do not self-extend treatment beyond the prescribed duration. All dosing is prescriber-determined.

• Tretinoin (0.045%): RAR agonist driving accelerated keratinocyte turnover, melanin dispersal, enhanced ingredient penetration, and reduced tyrosinase activity via retinoid receptor pathways.
• Hydroquinone (6%): Competitive inhibitor of tyrosinase via substrate analog competition, blocking the committed step of melanin synthesis; also directly damages melanocytes and melanosomes at higher concentrations.
• Desonide (0.05%): Low-potency glucocorticoid receptor agonist that induces phospholipase A2 inhibitory proteins (lipocortins), reducing arachidonic acid release, prostaglandin synthesis, and subsequent melanocyte activation. Also reduces leukocyte and macrophage infiltration, which is critical in inflammatory hyperpigmentation. Desonide minimizes treatment-induced irritation by attenuating retinoid and hydroquinone-related inflammation, thereby preventing PIH from treatment itself—an important consideration with high-potency depigmenting regimens.
• Kojic Acid (4%): Chelates the copper ion in the active site of tyrosinase, inhibiting enzyme activity without direct substrate competition (complementary to hydroquinone). Also provides antioxidant activity, protecting melanocytes from oxidative stimuli that trigger melanogenesis.

This four-agent formulation is used for severe or recalcitrant melasma, significant PIH, and complex hyperpigmentation syndromes requiring simultaneous multi-pathway attack. The Kligman formula concept (tretinoin + hydroquinone + corticosteroid) forms the historical basis for this approach; kojic acid is added as a fourth complementary tyrosinase inhibitor for enhanced efficacy.

Monitoring considerations:

• Limit continuous use to 3–6 months due to risks of hydroquinone ochronosis and corticosteroid-induced skin atrophy
• Monitor for corticosteroid-related side effects with prolonged use (skin atrophy, telangiectasias, striae, perioral dermatitis)
• Monitor for contact dermatitis from kojic acid (common at higher concentrations)
• Strict sun protection counseling with re-evaluation at each visit
• HPA axis suppression risk is low with desonide 0.05% applied to small areas, but consider in patients with extensive application

Contraindications:

• Hypersensitivity to any component
• Active skin infection at application site
• Pregnancy (avoid tretinoin/hydroquinone first trimester; corticosteroids—minimize use)
• Application to large surface areas (systemic corticosteroid and hydroquinone absorption)

Warnings & Precautions:

• Hydroquinone: ochronosis risk with prolonged use; limit continuous treatment to 3–6 months
• Desonide: skin atrophy, telangiectasias, striae, and HPA axis suppression with prolonged use; avoid occlusion
• Tretinoin: photosensitivity—mandatory daily sunscreen
• Kojic acid: contact sensitization, especially at >1% concentration; discontinue if rash/dermatitis occurs
• Compound additive irritation: all four agents can cause dryness, erythema, and peeling

Drug Interactions:

• Concurrent oxidizing agents: inactivate tretinoin
• Other corticosteroids: avoid concurrent topical corticosteroids to prevent HPA suppression

Common Side Effects: Erythema, peeling, dryness, burning, contact dermatitis (kojic acid), and skin thinning with prolonged corticosteroid use.

Store at room temperature (15–25°C) in sealed, opaque packaging protected from light and air. Hydroquinone and kojic acid are both subject to oxidation; a darkened or brown color indicates degradation—discard the preparation. Do not freeze. Use within the Genesis Compounding-assigned beyond-use date.

Why does this formula contain a steroid (desonide)?

Inflammation is a major driver of post-inflammatory hyperpigmentation (PIH). When tretinoin and hydroquinone cause irritation, that irritation can paradoxically darken the skin. Desonide, a very mild steroid, prevents this cycle by controlling treatment-induced inflammation—an approach pioneered by the classic Kligman formula for melasma.

Why are both hydroquinone and kojic acid included?

Both inhibit tyrosinase (the key melanin-making enzyme), but through different mechanisms: hydroquinone competes at the active site, while kojic acid chelates the copper ion needed for enzyme function. Using both provides complementary inhibition, potentially overcoming resistance to either agent alone.

How long can I use this formula?

Due to ochronosis risk from hydroquinone and skin thinning risk from the corticosteroid, continuous use is generally limited to 3–6 months. Your prescriber will establish a treatment cycle and maintenance plan.

Do I need to wear sunscreen while using this?

Yes—this is non-negotiable. UV exposure drives melanogenesis and will cause rapid repigmentation, negating the treatment. Apply SPF 30+ broad-spectrum sunscreen every morning.

Is this FDA-approved?

This is a 503A compounded preparation by Genesis Compounding. No FDA-approved product contains all four ingredients at these concentrations; compounding allows this individualized multi-agent approach.